For several years, Pradaxa, Elliquis, and Xarelto have had the market cornered on sales of New Oral Anticoagulants (NOACs) as treatment for patients who suffer from a serious medical condition known as atrial fibrillation (Afib). NOACs are an entirely new class of drugs designed to replace conventional blood thinners, such as Coumadin (Warfarin).
However, Daiichi Sankyo has recently entered the market with its own NOAC product under the name Savaysa. The company has high hopes for Savaysa sales, given that it recently lost its patent for Benicar, according to a recent news article from Fierce Pharma. Benicar, which will soon be available as a generic, is responsible for around 27 percent of Daiichi sales, so this loss will hurt. The company is hoping to make up for that loss with sales of their new drug, Savaysa, but they are running into some stumbling blocks. Continue reading
Product Liability Lawyer Blog











